Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PBYI – Puma Biotechnology, Inc.

Puma Biotechnology Inc
PBYI
$4.97
Name : Puma Biotechnology Inc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $250,191,856.00
EPSttm : 0.74
finviz dynamic chart for PBYI
Puma Biotechnology Inc
$4.97
1.53%
$0.075

Float Short %

8.76

Margin Of Safety %

42

Put/Call OI Ratio

0.09

EPS Next Q Diff

-0.13

EPS Last/This Y

-0.09

EPS This/Next Y

-0.14

Price

4.89

Target Price

3.5

Analyst Recom

4

Performance Q

-2.3

Relative Volume

0.76

Beta

1.17

Ticker: PBYI




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-20PBYI5.450.030.124460
2025-10-21PBYI5.180.030.334467
2025-10-22PBYI5.230.031.754514
2025-10-23PBYI5.030.030.654531
2025-10-24PBYI5.220.050.004625
2025-10-27PBYI5.280.050.134734
2025-10-28PBYI5.260.042.504740
2025-10-29PBYI5.170.040.204744
2025-10-30PBYI5.470.050.004740
2025-10-31PBYI5.110.051.114719
2025-11-03PBYI5.040.050.044765
2025-11-04PBYI4.910.05999.994840
2025-11-05PBYI4.940.060.004891
2025-11-06PBYI4.90.060.004899
2025-11-07PBYI5.980.060.094936
2025-11-10PBYI4.730.050.474894
2025-11-11PBYI5.190.080.925204
2025-11-12PBYI4.980.090.005244
2025-11-13PBYI4.950.090.005245
2025-11-14PBYI4.890.090.005239
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-20PBYI5.45-80.0- 0.70
2025-10-21PBYI5.18-80.0- 0.70
2025-10-22PBYI5.23-80.0- 0.70
2025-10-23PBYI5.04-80.0- 0.70
2025-10-24PBYI5.22-80.0- 0.70
2025-10-27PBYI5.28-80.0- 0.70
2025-10-28PBYI5.25-80.0- 0.70
2025-10-29PBYI5.17-80.0- 0.70
2025-10-30PBYI5.46-80.0- 0.70
2025-10-31PBYI5.10-80.0- 0.70
2025-11-03PBYI5.04-80.0- 0.70
2025-11-04PBYI4.91-80.0- 0.70
2025-11-05PBYI4.95-80.0- 0.70
2025-11-06PBYI4.91-80.0- 0.70
2025-11-07PBYI5.99-80.0- 0.70
2025-11-10PBYI4.73- - 0.70
2025-11-11PBYI5.19- - 0.70
2025-11-12PBYI4.97- - 0.70
2025-11-13PBYI4.95- - 0.70
2025-11-14PBYI4.89-46.5- 0.69
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-20PBYI-1.436.129.32
2025-10-21PBYI-1.436.129.32
2025-10-22PBYI-1.436.129.32
2025-10-23PBYI-1.436.129.32
2025-10-24PBYI-1.436.129.32
2025-10-27PBYI-1.435.688.91
2025-10-28PBYI-1.435.688.91
2025-10-29PBYI-1.435.688.91
2025-10-30PBYI-1.435.688.91
2025-10-31PBYI-1.435.688.91
2025-11-03PBYI-1.465.638.84
2025-11-04PBYI-1.465.638.84
2025-11-05PBYI-1.465.638.84
2025-11-06PBYI-1.465.638.84
2025-11-07PBYI-1.465.638.84
2025-11-10PBYI-1.465.618.84
2025-11-11PBYI-1.465.618.84
2025-11-12PBYI-1.465.618.79
2025-11-13PBYI-1.465.618.79
2025-11-14PBYI-1.625.618.76
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

0.17

Avg. EPS Est. Current Quarter

0.23

Avg. EPS Est. Next Quarter

0.04

Insider Transactions

-1.62

Institutional Transactions

5.61

Beta

1.17

Average Sales Estimate Current Quarter

68

Average Sales Estimate Next Quarter

49

Fair Value

6.95

Quality Score

97

Growth Score

40

Sentiment Score

21

Actual DrawDown %

65.4

Max Drawdown 5-Year %

-88

Target Price

3.5

P/E

6.6

Forward P/E

10.88

PEG

P/S

1.16

P/B

2.14

P/Free Cash Flow

5.75

EPS

0.74

Average EPS Est. Cur. Y​

0.69

EPS Next Y. (Est.)

0.55

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

17.44

Relative Volume

0.76

Return on Equity vs Sector %

5.2

Return on Equity vs Industry %

20

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

Puma Biotechnology Inc
Sector: Healthcare
Industry: Biotechnology
Employees: 172
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
stock quote shares PBYI – Puma Biotechnology, Inc. Stock Price stock today
news today PBYI – Puma Biotechnology, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PBYI – Puma Biotechnology, Inc. yahoo finance google finance
stock history PBYI – Puma Biotechnology, Inc. invest stock market
stock prices PBYI premarket after hours
ticker PBYI fair value insiders trading